

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

Angela N. Johnson, MSE, PMP, RAC

Angela.Johnson@Sigilon.com / Angela.Johnson@ttu.edu

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

General Disclaimer: This presentation represents my own opinions and does not represent the view or opinions of my employer, either Sigilon Therapeutics, Inc. or Texas Tech University, or any past employer. This presentation may contain forward-looking statements. These statements are based on the presenter's opinion(s) and publicly available information at the time of this presentation. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date on which they are made.

Contents are © 2020 Angela Johnson

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM



Angela N. Johnson, MSE, PMP, RAC

Sr. Director Regulatory Affairs

Angela.Johnson@Sigilon.com

Angela@angelanjohnson.com



TEXAS TECH
UNIVERSITY

- 15+ years strategic leadership of clinical trials projects in cell and gene therapy, medical devices, and combination products
- Prior Sr Manager of Clinical Operations for GE Healthcare, and Director of Strategic Development of Quintiles/IQVIA
- ASGCT Government Relations Board Member
- ARM EU and US Regulatory Committee Member
- Author of 2017 Medical Devices, and 2019 Gene & Cell Therapy chapters in Best-selling RAPS regulatory strategy textbooks



Agencies Wrote the Regulations.
We Wrote the Book.

Fundamentals of US Regulatory Affairs, 10th Edition



Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

Agenda

Today's discussions are an opportunity for participants to get together in an informal setting to examine issues as they relate to their careers. There is no formal agenda, but there are specific topics. We will plan to spend ~15-20 min on each.

1. **About You** – Tell us about your experience in combination products & diagnostics
2. **Classification, Types of Combos & Diagnostics, & Development Issues**
 - a. **FDA Issues** for combination products
 - b. **EU MDR & Global** issues for combination products
3. **Co-development and Platform Development Issues:** Diagnostic platforms, co-development in oncology & advanced therapies, and other issues

... remaining time for open discussion

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

About You

~ 2:50 - 3:05 PM (15 min)

“When people tell me they’ve learned from experience, I tell them the trick is to learn from other people’s experience”

- Warren Buffett

We will spend ~15 min learning about you and your combo & diagnostic experiences.

Can you share:

1. Your name, role, and company
2. How do you work with combination products and/or diagnostics in your role?
3. What was the biggest challenge you encountered with combination products and/or diagnostics in the last year? Ever?
4. What policy, industry, or other changes could improve those challenges?
5. What is most exciting about combination products and/or diagnostics? (e.g. could be a news article, an event a product, or a new technology)

Conversation Starters

Can you share:

1. Your name, role, and company
2. How do you work with combination products and/or diagnostics in your role?
3. What was the biggest challenge you encountered with combination products and/or diagnostics in the last year? Ever?
4. What policy, industry, or other changes could improve those challenges?
5. What is most exciting about combination products and/or diagnostics? (e.g. could be a news article, an event a product, or a new technology)

Themes from our
about us
conversations

Sharing Ideas

First drug-device
combo product for
my company, which
is a drug company

Similarities between
rare disease space
and precision
oncology

Devices that can be
used for drug
delivery as combo
products

Digital devices
(inhalers) are tricky
development,
unclear regulatory
landscape;
experience on both
sides of drug &
device

Moving into the
regulatory affairs
world, first
combination product,
biosimilar hurdles

Subcutaneous drug
delivery and
injectables, many
require device
components (e.g.
autoinjectors) and
intrinsic devices

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM


Combo Classification & Development Issues (US)

~ 3:05 - 3:25 PM (15 min)

“FDA expects to receive large numbers of combination products for review as technological advances continue to merge product types and blur the historical lines of separation between FDA’s medical product centers”

- About Combination Products, FDA

Overview of FDA Medical Device & Diagnostic Pathways



Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

Combo Classification & Development Issues (US)


~ 3:05 - 3:25 PM (15 min)

“FDA expects to receive large numbers of combination products for review as technological advances continue to merge product types and blur the historical lines of separation between FDA’s medical product centers”

- About Combination Products, FDA

FDA CDER

FDA CBER



FDA CDRH

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

Combo Classification & Development Issues (US)


~ 3:05 - 3:25 PM (15 min)

“FDA expects to receive large numbers of combination products for review as technological advances continue to merge product types and blur the historical lines of separation between FDA’s medical product centers”

- About Combination Products, FDA

US FDA Resources and Considerations for Combo Products

- Combination product is defined as any combination of drug, biologic and device per 2 CFR 3.2(e), may be “single entity” (chemically combined), “co-packaged”, or “cross-labelled” for use with another product
- FDA Office of Combination Products (OCP)
“OCP welcomes comments from interested stakeholders on any policy issues that you believe should be addressed or clarified in guidance, regulations or otherwise. OCP also encourages medical product developers to contact us if they are uncertain about the classification or assignment of their products and with questions regarding premarket or postmarket considerations for combination products.” – [FDA](#)
- Guidance: How to Write a Request for Designation (RFD) ([FDA 2011](#))



- Designation discussions at Pre-IND and other meetings

Conversation Starters

1. Insights from FDA meeting experiences?
2. Issues with the RFD Process?
3. CMC issues with combo products?
4. Other experiences related to US FDA combo products...

Example: This is an idea we discussed

Example: This is a question raised by the group

US FDA Combo Product Issues & Experience

Precision oncology, CDx - PMA approval at BLA vs. post-market; best strategies for FDA?

Companion Diagnostics (CDx) development? IDE or not? PMA before or after NDA/BLA?

Human factors - how much is enough? Why do changes come in at the last minute

Predictive software for risk stratification etc. faces similar issues when used in diagnostic

COVID related meeting delays, resource issues

How has FDA structure changed?

510(k) cleared devices used in products development, to label as investigational or not? IDE or not?

CDRH & Other center interaction - staffing level? Resources? Timeframes? Tend towards longer

Surprises = change in human factors requirements

Sometimes unexpected timeframes, last min questions from CDRH- other disciplines like engineers & physicists

Human factors reviewers in CDER itself (medication error prevention) vs. CDRH Human factors

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM


Combo Classification & Development Issues (EU)

~ 3:25 - 3:40 PM (15 min)

“FDA expects to receive large numbers of combination products for review as technological advances continue to merge product types and blur the historical lines of separation between FDA’s medical product centers”

- About Combination Products, FDA

EU MDR & IVDR Timelines



* On April 3rd, 2020 the European Commission proposed a one-year **delay** of the Medical Devices Regulation (**MDR**) to the European Parliament and Council. Originally the Date of Application (DoA) was set on **May 26th**, 2020, but would move to **May 26th**, 2021 according to the EC proposal.

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM


Combo Classification & Development Issues (EU)

~ 3:25 - 3:40 PM (15 min)

“FDA expects to receive large numbers of combination products for review as technological advances continue to merge product types and blur the historical lines of separation between FDA’s medical product centers”

- About Combination Products, FDA

Overview of EU Medical Device & In Vitro Diagnostic Pathways (MDR)*



*EU IVD Directive originally established IVD Classes “general”, “Self-testing”, “List B” and “List A” IVDR replaced these with Class A, B, C & D

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

Combo Classification & Development Issues (EU)

~ 3:25 - 3:40 PM (15 min)

“The demarcation between medicinal products and devices is becoming ever more important and, with the convergence of emerging novel technologies in Europe”

- [Businesswire London](#)

EU Resources and Considerations for Combo Products

1. The EU historically did not have a category of product for combinations. The new Medical Device Regulation (MDR) supersedes the previous Medical Devices Directive (MDD), separating Drug-Device Combinations (DDCs) into two categories:
 - Article 1(8) Devices incorporating as an **integral part a substance** that, if used separately, would be considered a medicinal product *and* the action of the substance is principal.
 - Article 1(9) Devices intended **to administer a medicinal product** where they form a **single integral product** intended exclusively for use in the given combination which is not reusable.
2. “Borderline Products” remain an issue in EU
3. Per Regulation (EU) 2017/745 on medical devices Article 117, future MAAs should include a CE certificate or declaration of conformity for the device or, in certain cases, an opinion from a notified body (NB) on the conformity for device components.
4. Guideline: Quality requirements for drug-device combinations ([EMA Draft 2019](#))
5. Discussions of Combination Products at Scientific Advice Meetings and with Notified Bodies

Conversation Starters

1. Insights from EU SA meeting experiences?
2. Issues with the combination product classification?
3. CMC issues with combo products?
4. Other global experiences related to combo products...

Example: This is an idea we discussed

Example: This is a question raised by the group

EU & Global Combo Product Issues & Experience

Is EU or FDA development more complex faster?

For combos we observe EU is faster in early phase, similar by time of marketing applications

Japan / APAC experience

High early costs of Development in early phase

Japan and Korea has had more questions (e.g. pre-filled syringe, asked more on raw materials etc.)

UK also asked a lot of detailed questions on materials etc.

Other issues in EU...? Should we take combos to EU first?

ATMP products in EU, such as cell scaffolding and matrix- no DMF equivalent, recent changes in regulation

Brexit - with UK MHRA leaving EU, innovation in UK may look different... we notice more strict questions on materials for devices

Drug-Device Combination Treatments & Diagnostics

Workshop 2:50 - 3:50 PM

Codevelopment & Issues in Emerging Tech


~ 3:40 - 3:55 PM (10 min)

“Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market”

- ResearchandMarkets.com

FDA

- Guidance: Codevelopment of Two or More New Investigational Drugs for Use in Combination ([FDA June 2013](#))
- Guidance: Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry ([FDA Oct 2019](#))
- Draft Guidance: Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product ([FDA July 2016](#)), enabling concurrent trials of a therapeutic & IVD



EMA

- Guideline: Co-development of pharmacogenomic biomarkers and assays in the context of drug development ([EMA 2010](#))
- Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle ([EMA 2017](#))
- Impact of new MDR and IVDR regulations

Drug-Device Combination Treatments & Diagnostics

Roundtable Workshop 2:50 - 3:50 PM

Codevelopment & Issues in Emerging Tech

~ 3:40 - 3:55 PM (10 min)

“Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market”

- [ResearchandMarkets.com](https://www.researchandmarkets.com)

Other issues in codevelopment

- Codevelopment often occurs as a result of partnership between device and drug companies, leveraging each's unique expertise. This model differs from traditional business licensing and partnership strategy, and can reduce risk
- An increasing number of new oncology therapeutics and advanced therapies (e.g. gene therapy) require highly specific companion IVDs, requiring US PMA and Class III device registration in EU
- Clinical trials can run in parallel, with samples are data “feeding” into another trial, typically a therapeutic trial feeding a diagnostic.
- Digital therapeutics (DTx) and software as a medical device (SaMD, e.g. clinical decision-support software) may be developed alongside traditional therapeutics
- FDA allows hybrid “streamlined” cGMP-QSR for drug-device combos
- The future in EU may mean CE mark “duplicate” requirements apply to MAA products with device components

Conversation Starters

1. Experiences with codevelopment?
2. Codevelopment challenges
3. Advanced therapy & companion diagnostics issues?
4. Other topics in combos and co-development

Example: This is an idea we discussed

Example: This is a question raised by the group

Codevelopment and Tech Issues in Device & IVD

When should we engage with FDA? to OCP?

Early stage with combos can be challenges for new products, based on company experience

Early engagement with FDA to streamline regulatory issues is critical

Bring your proposed development process to FDA, and proposes classification

Teams within regulatory and R&D have to align, especially with software involved

What about digital therapeutics (DTx) and digital diagnostics?

Privacy, interoperability, cybersecurity may be new areas in devices most companies less familiar with

Drug-Device Combination Treatments & Diagnostics

Roundtable Workshop 2:50 - 3:50 PM

Discussion and Q&A
Thank you
for attending and sharing your expertise

Angela N. Johnson, MSE, PMP, RAC

Angela.Johnson@Sigilon.com / Angela.Johnson@ttu.edu



TEXAS TECH
UNIVERSITY